Pharma Stock in Focus After Agreement to Acquire Remaining 12% Stake in Its Subsidiary
A pharmaceutical company is making headlines after announcing a Rs. 231.87 crore acquisition to take full ownership of its biologics subsidiary, aiming to bolster its biotechnology sector.
Editorial Staff
1 min read
Updated about 21 hours ago
The shares of the pharmaceutical company have gained significant attention following the announcement of its acquisition deal.
This strategic move involves acquiring the remaining 12% stake in its biologics subsidiary, which is expected to strengthen its position in the biotechnology market.
The acquisition is valued at Rs. 231.87 crore, reflecting the company's commitment to expanding its operations and enhancing its product offerings.